Table 1.
Epidemiology and characteristics of NAFLD/NASH-HCC.
| Year | Authors | PMID | Country | Statistics time (years) | Patient source | Race | Total people | Male | NAFLD/ NASH-HCC ratio | NAFLD/NASH-HCC-NCL ratio |
|---|---|---|---|---|---|---|---|---|---|---|
| 2008 | Grace G et al. | 18976012 | USA | 2004–2007 | The University of Illinois at Chicago Medical Center | N | 50 | 66.7% (2/3) | N | 6% (3/50) |
| 2009 | Chagas AL et al. | 19787150 | Brasil | 1998–2006 | Department of Gastroenterology of Clinic Hospital of University of São Paulo School of Medicine | N | 394 | 57% (4/7) | 1.7% (7/394) | 14.2% (1/7) |
| 2009 | Paradis V et al. | 19115377 | France | 1995–2007 | Beaujon Hospital | N | 128 | 96% (30/31) | 24% (31/128) | 35% (11/31) |
| 2009 | Kawada N et al. | 19672551 | Japan | 1990–2006 | Osaka Medical Center for Cancer and Cardiovascular Diseases | N | 807 | 50% (3/6) | 1% (8/807) | 75% (6/8) |
| 2011 | Ertle J et al. | 21128245 | Germany | 2007–2008 | Department of Gastroenterology and Hepatology at University Hospital Essen | Central Europe: 125, Southern Europe: 14, Eastern Europe: 4, Asia: 7 | 162 | 83.3% (125/162) | 24% (36/162) | 11% (4/36) |
| 2012 | Duan XY et al. | 22251466 | China | 1990–2010 | Pubmed database | Australia: 1, Brazil: 1, Japan: 80, France: 23, UK: 2, Spain: 2, USA: 24, Germany: 36 | 169 | 72.8% (123/169) | 100% (169/169) | 40% (68/169) |
| 2013 | Alexander J et al. | 23302015 | USA | 1990–2010 | Three tertiary care centers in the United States | N | 157 | 64% (101/157) | 15.3% (24/157) | N |
| 2014 | Schütte K et al. | 24990270 | Germany | 1994–2013 | The University Hospital of Magdeburg | N | 664 | 73% (68/93) | N | 14% (93/664) |
| 2015 | Perumpail RB et al. | 26250831 | USA | 2010–2012 | Brooke Army Medical Center (BAMC) | N | 44 | 83.3% (5/6) | N | 13.6% (6/44) |
| 2015 | Mohamad B et al. | 26558795 | USA | 2003–2012 | Cleveland Clinic Foundation | White: 77,African American: 4,other: 2 | 83 | 65% (54/83) | N | 43% (36/83) |
| 2015 | Leung C et al. | 25632192 | Australia | 2000–2012 | The Victorian Liver Transplant Unit | N | 54 | 87% (47/54) | 13% (39/54) | 20.5% (8/39) |
| 2015 | Weinmann A et al. | 25884354 | Germany | 2000–2010 | University Medical Centre of the JohannesGutenberg University Mainz | Caucasian origin: 1100 (98.3%) | 1119 | 77.8% (35/45) | 4.0% (45/1119) | N |
| 2015 | Younossi ZM et al. | 26274335 | USA | 2004–2009 | Surveillance, Epidemiology and End Results (SEER)-Medicare linked database | White: 3031 (60.9%) Other: 1348 (39.1%) | 4 979 | 61.3% (430/401) | 14.1% (701/4979) | N |
| Year | HCC-NCL tumor diameter (cm) | HCC-NCL tumor status | HCC-NCL age (years) | HCC-NCL influencing factor | HCC-NCL treatment | Mortality rate | Recurrence rate | Reference |
|---|---|---|---|---|---|---|---|---|
| 2008 | 0.5–10 | N | 57±13 | Obesity, diabetes, hypertension, dyslipidemia | N | N | N | 77 |
| 2009 | 1.0–5.2 | A single nodule: 57% | 63±13 | Obesity, hypertension, dyslipidemia, hyperuricemia | N | N | N | 6 |
| 2009 | N | A single nodule: 78% | 67±7 | Obesity, diabetes, hypertension, dyslipidemia | N | N | N | 9 |
| 2009 | N | N | N | Obesity, diabetes, hypertension, dyslipidemia | Hepatic resection: 100% | N | N | 23 |
| 2011 | N | N | 68.6±8.4 | Obesity, diabetes, hypertension, dyslipidemia | N | N | N | 5 |
| 2012 | 0.8–20 | A single nodule: 76% | 67 | Obesity, diabetes, hypertension, dyslipidemia | Tumor resection: 57.7%, liver transplantation: 14.6%, percutaneous ethanol injection: 3.1%, radiofrequency ablation: 8.5%, transarterial embolization: 19.2%, transarterial infusion chemotherapy: 1.5%,microwave coagulation therapy: 0.8% | 32,40% | 18,80% | 10 |
| 2013 | N | N | 63.8±12.5 | Diabetes, hypertension, dyslipidemia | Hepatic resection: 100% | N | N | 90 |
| 2014 | N | N | 69 (32–85) | Obesity, hypertension | Resection: 23.66%,RFA/thermoablation: 5.38%, liver transplantation: 1.08% | N | N | 35 |
| 2015 | N | N | 72±8 | Obesity, diabetes, hypertension, dyslipidemia | Right hepatectomies: 33%, core liver biopsies: 50% | N | N | 11 |
| 2015 | N | A single nodule: 80.6% | 67.5±12.3 | Obesity, positive family history of cancer, diabetes, metabolic syndrome, hypertension, smoking, alcohol consumption | Hepatic resection: 66.7%, loco-regional therapy: 22.3% | 47% | 86% | 32 |
| 2015 | 4,7 | N | 65 | Obesity, diabetes, hypertension, dyslipidaemia | Liver transplantation: 12.5% | N | N | 34 |
| 2015 | 1.5–16.5 | N | 67.6 | Obesity, diabetes, hypertension, cardiovascular complications, dyslipidemia, myocardial infarction, apoplectic stroke, thrombocytopenia | Resection or orthotopic liver transplantation: 4.4% | N | N | 46 |
| 2015 | N | N | 73±8 | Male, race, any type of chronic liver diseases | Liver transplantion: 5.7% | 61.20% | N | 84 |
N – not repotred.